Music Therapy Experiences in Patients With Mild Cognitive Impairment (MCI) and Alzheimer's Disease (AD)
This study compares different music therapy (MT) experiences and their impact on memory and
language in patients with Alzheimer's disease and Mild Cognitive Impairment.
The 12-month study will assess the role of common experiences involving familiar music and
ot...
Age: 55 years - 66+
Gender: All
AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid
The primary purpose of this study is to determine whether treatment with lecanemab is
superior to placebo on change from baseline of the Preclinical Alzheimer Cognitive Composite
5 (PACC5) at 216 weeks of treatment (A45 Trial) and to determine whether treatment with...
Age: 55 - 80 years
Gender: All
Locus-coeruleus Function in Normal Elderly and AD Risk
Growing evidence suggests that Alzheimer's disease (AD) pathological changes begin decades
before clinical symptoms and tau abnormalities in the locus coeruleus (LC) can be observed
since midlife. We have previously demonstrated functional vulnerability of the LC to...
Age: 60 - 75 years
Gender: All
A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205
The primary objective is to evaluate the long-term safety and tolerability of aducanumab
after a wash-out period imposed by discontinuation of feeder studies in participants who had
previously received aducanumab (i.e. previously treated participants) or who had pre...
Age: Birth - 66+
Gender: All
The Long-term Impact of a Light Intervention on Sleep and Cognition in Mild Cognitive Impairment
To investigate the impact of a long-term light treatment intervention on sleep physiology and
memory in mild cognitively impaired and mild Alzheimer's disease patients living at home. The
goal is also to measure the impact of the lighting intervention on caregivers'...
Age: 65 years - 66+
Gender: All
Light, Metabolic Syndrome and Alzheimer's Disease
To test the long term effect of a light treatment on cognition, sleep and metabolism in
patients with Mild cognitive impairment (MCI) or mild Alzheimer's disease or related dementia
(ADRD).
Age: 55 years - 66+
Gender: All
Light and the Effect on Metabolic Syndrome and Alzheimer's Disease
This study's main hypothesis is that a delivering a tailored lighting intervention (TLI) will
provide a successful means for promoting circadian entrainment and treating metabolic disease
and inflammation in patients with mild cognitive impairment (MCI) and Alzheime...
Age: 55 years - 66+
Gender: All
Alzheimer's Disease Neuroimaging Initiative 3 (ADNI3) Protocol
Since its launch in 2004, the overarching aim of the Alzheimer's Disease Neuroimaging
Initiative (ADNI) has been realized in informing the design of therapeutic trials in AD.
ADNI3 continues the previously funded ADNI-1, ADNI-GO, and ADNI-2 studies that have been
...
Age: 55 - 90 years
Gender: All
An Efficacy and Safety Study of JNJ-54861911 in Participants Who Are Asymptomatic at Risk for Developing Alzheimer's Dementia
The purpose of this study is to evaluate whether treatment with JNJ-54861911 slows cognitive
decline compared with placebo treatment, as measured by a composite cognitive measure, the
Preclinical Alzheimer Cognitive Composite (PACC), in amyloid-positive participants w...
Age: 60 - 85 years
Gender: All